Zoonosis: Brucellosis in Animals and Humans

This is a curated page. Report corrections to Microbewiki.

Introduction

By Hannah Wedig

Figure 1. The phylogeny of the genus Brucella aligned with the phylogeny of their respective, preferred host species. The width of the cones in the Brucella phylogeny is proportional to the number of strains analyzed for that species. The host phylogeny is represented in millions of years. [1]

Brucellosis is among the most common and highly contagious zoonoses. Zoonoses are diseases which can be transmitted from animals to humans. In the case of brucellosis, mammals – domestic, wild, terrestrial, and marine – are capable of transmitting the disease. Brucellosis is caused by certain species of bacteria in the genus Brucella, the most common and virulent of which are B. melitensis, B. suis, and B. abortus (Figure 1). The genus Brucella is within the class α-Proteobacteria, which includes many bacterial parasites of both plants and animals.

All Brucella are small (≈ 0.5µm-1.5µm in diameter), sessile, Gram-negative coccobacilli, and are facultative intracellular pathogens (Figure 2). When cultured, Brucella colonies appear either smooth or rough. Smooth colonies are more common in the virulent species of Brucella (e.g. B. melitensis, suis, and abortus), and rough colonies are associated with non-virulent species. The rough morphotype is attributed to a lipopolysaccharide molecule that elicits strong immune responses in animals, which may explain why it is associated with the non-virulent species.

Figure 2. Colored scanning electron micrograph of B. melitensis. [9]

Brucella are capable of surviving, but rarely reproduce, in external environments for well over a year given the appropriate conditions. They fare best in environments with a pH greater than 5.5, high humidity, and, most especially, freezing temperatures. In animals, Brucella can be found all over the globe, with notably high occurrences in the Mediterranean, Middle East, Latin America, and Africa. The highest incidences of Brucella in humans are recorded in Syria and Mongolia (Figure 3).

Figure 3. Global occurrences of brucellosis in humans. The highest incidences are recorded in Syria (1603.4 incidences per 1M people per year), Mongolia (605.9 incidences per 1M people per year), and Kyrgyzstan (362.2 incidences per 1M people per year). The incidence of brucellosis in the United States is 0.4 per 1M people per year. [14]

The first concrete documentation of brucellosis symptoms in humans occurred in the 1850’s when a British Army surgeon, Dr. Jeffrey Marston, described a fever he had, the symptoms of which differed from any other known fever at the time. In 1887, the first species of Brucella (B. melitensis) was isolated from the spleens of Maltese soldiers who had come down with what was then called Malta fever (the earliest name for brucellosis). For nearly two decades, the transmission of this disease was a mystery and people generally attributed it to “bad air” and poor public sanitation. Finally, in 1904, a Maltese physician named Themistocles Zammit solved the mystery by performing a series of ethically questionable experiments on goats. He fed his goats cultures of Brucella, observed their symptoms, and tested their urine, blood, and milk for presence of the bacteria. Based on the results, he concluded that the disease’s causative agent was transmittable to humans through the ingestion of contaminated goat milk. A decade later, the abortive effects of Brucella in animals were discovered.

Transmission, Signs, and Symptoms

Themistocles Zammit had discovered the most common means of Brucella infection: ingestion of contaminated animal products (such as dairy products for humans, and aborted fetuses or placenta for animals). However, Brucella can also enter via the respiratory tract, broken skin, or any mucous membranes that come into contact with infected fluids or tissues (such as feces, urine, milk, fetal fluids, vaginal discharge, semen, placenta, aborted fetuses, etc.).

In humans, Brucella primarily inhabit parts of the phagocytic system including lymph nodes, liver, spleen, and bone marrow. The incubation period can range from one to three weeks, during which the cells remain in the phagocytic system and replicate. Because of this, symptoms may be entirely absent up to several months after infection. The symptoms, once they arise, have been described as so bad “‘it often makes a patient wish he were dead”. Human brucellosis caused by B. melitensis was first known as Malta fever (though it has an abundance of other names, such as Mediterranean fever, Corps disease, undulant fever, and Cyprus fever, to name a few), an illness characterized by fatigue and back pain in addition to elevated body temperatures.

Figure 4. The various transmission pathways of B. melitensis. Pasteurization, fermentation, exposure to sunlight, and infection of certain paratenic hosts such as horses or humans are considered dead ends in that they either kill or prevent significant transmission of Brucella. [1]

Other species of Brucella can cause a range of sequelae including anorexia, myalgia, encephalitis, meningitis, endocarditis, and various forms of arthritis. Although rarely fatal, if left untreated, brucellosis can become a chronic, debilitating disease. It is also not uncommon for infected individuals to relapse as early as several months after recovering from the initial infection.

In animals, Brucella can inhabit an array of organs, including the aforementioned ones in the phagocytic system but also the kidneys and reproductive organs. If a pregnant female is infected, the bacteria can cause premature birth or spontaneous abortion of the fetus – this can also occur in female humans, but is much less common. Most infected female animals will only abort once but, if untreated, their placenta can retain the bacteria and cause complications in subsequent birthings.

Brucella have also been isolated from a range of arthropods including ticks, bedbugs, lice, and mites. Though these hosts are paratenic, meaning they are not necessary constituents of the Brucella life cycle, they can function as brucellosis vectors.

As previously mentioned, Brucella fare best in cooler conditions and are extremely susceptible to heat – a mere hour or two of exposure to direct sunlight will kill the bacteria. In addition to sunlight exposure, mammals that are resistant to the bacteria or those that rarely pass on the bacteria (such as humans) are considered “dead ends” in terms of bacterial transmission (Figure 4).

Major Brucella Species

Terrestrial Brucella

B. melitensis: Among the ten known species of Brucella, B. melitensis is the most common and most pathogenic for humans. Sheep and goats are the predominant natural hosts of B. melitensis, but it has been isolated from a vast array of other mammals including humans, cattle, deer, squirrels, guinea pigs, mice, hedgehogs, fox, dogs, cats, chickens, and frogs. B. melitensis is aerobic, and does not require supplementary CO₂ to grow (see B. abortus).

B. suis: B. suis is most commonly found in domestic pigs and wild boars, but can also inhabit humans, peccary, cattle, moose, horses, bears, fox, voles, ravens, and turkeys. Like B. melitensis, B. suis is aerobic and does not rely on increased levels of CO₂ for growth. Unlike B. melitensis, certain subspecies of B. suis produce H₂S during growth. The pathogenicity of B. suis is variable, but is typically less virulent than B. melitensis and more virulent than B. abortus.

B. abortus: B. abortus typically infects cattle, bison, yaks, buffalo, and sheep, but has also been discovered in humans, deer, horses, coyotes, fox, badgers, raccoons, and opossums. B. abortus is aerobic and also typically requires an atmosphere with about 5-10% CO₂ to grow. Though B. abortus causes spontaneous abortions in animals, the infection tends to be subclinical in humans.

Aquatic Brucella

B. ceti and B. pinnipedialis: These two species of Brucella preferentially infect cetaceans (i.e. whales, dolphins, etc.) and pinnipeds (i.e. seals), respectively. Both have been isolated from various tissues of cetaceans and pinnipeds that appeared perfectly healthy, suggesting that their virulence is much milder compared to the terrestrial species. When B. ceti does cause disease, it is quite diverse in its effects, as it can cause blubber abscesses, lesions, organ inflammation, pneumonia, and meningitis, to name a few. Strains of B. ceti and B. pinnipedialis are variable in their zoonotic capabilities, but in general they are considered non-zoonotic. One strain (B. ceti Hum) can infect humans in the same fashion as the terrestrial Brucella, other strains can infect humans but are killed off by the immune system almost immediately, and others still are incapable of infecting humans altogether. B. ceti and B. pinnipedialis differ slightly in their metabolic requirements – B. pinnipedialis, like B. abortus, requires supplementary CO₂ to grow, and B. ceti, like B. melitensis and B. suis, does not.

Brucellosis in Humans

Though brucellosis was officially identified in the mid 19th century, the earliest record of brucellosis in humans dates back to nearly 2 million years ago, where the bacteria was discovered in the bone of an Australopithecine (one of the earliest hominids). Currently, the global incidence of human brucellosis is about 500,000 cases per year, but the number of unreported or undetected cases is hypothesized to be significantly greater. As previously mentioned, humans are generally considered a dead end for the transmission of Brucella, but it was recently determined that human-to-human transmission can occur. Initially, brucellosis was thought to only be transmitted between humans via operations such as blood transfusions or bone marrow transplants, but cases of infected individuals’ spouses or partners contracting the disease invalidated that contention. In 1991, a detailed case study revealed that brucellosis was indeed transmittable from humans to other humans, most likely via unprotected intercourse. Cases of infected mothers transmitting the disease to their infants via breast-feeding have also been documented. Not only does brucellosis present itself as a public health concern, it can also have detrimental economic impacts since livestock are the preferred hosts for the most virulent Brucella species. Furthermore, the potential manipulation of Brucella strains as biological weapons has contributed to the urgency of eradicating the disease.

Disease Management: Diagnostics, Treatment, and Prevention

Diagnostics

There is a diverse array of methods to diagnose brucellosis, the most common of which include observation of the clinical symptoms and serologic methods, i.e., by testing bodily fluids for presence of Brucella. Examples of common serologic methods include agglutination reactions (AR), complement fixation tests (CFT), and a test called BrucellaCapt (BCAP).

AR: Individuals infected with Brucella produce anti-Brucella agglutinins, which are antibodies that cause agglutination (i.e. clumping) of cells. The patient’s blood sample is deposited into a test tube, to which a solution of Brucella cells are added. If the antibodies are present, they bind to the bacterial cells and induce physiological changes which cause the cells to become hydrophobic and thus agglutinate at the bottom of the test tube and indicate Brucella infection. However, this diagnostic method lacks some specificity, as the agglutinins can cause the agglutination of other pathogenic bacteria including Francisella tularensis (the etiologic agent of tularemia), Rickettsia prowazekii (epidemic typhus), and Mycobacterium tuberculosis (tuberculosis). In addition, AR is unable to detect brucellosis in immunocompromised individuals, newly-infected individuals whose bodies have not yet produced the agglutinins, and individuals who have had brucellosis for longer than several weeks. Despite these drawbacks, AR is still used as the reference standard to which other serological tests are compared.

CFT: This test is more efficient than AR in terms of sensitivity (it is able to detect brucellosis in individuals who have been infected for over a year) and specificity, although the general concept is very much the same – testing for the presence of anti-Brucella antibodies in patients’ bodily fluids. The fluid sample is first heated to eliminate any existing antibody complements, after which a known amount of complements and antigens are added to the serum. If antibodies are present, they will bind (i.e. fix) the complements and antigens; if not, the complements and antigens will remain dispersed in the serum. Red blood cells from a different animal species and their respective antibodies are then added to the serum. If the previously added complements are fixed by anti-Brucella antibodies, the animal antibodies will fix the red blood cells and aggregate at the bottom of the test tube. If the complements are not fixed (that is, anti-Brucella antibodies are not present), the complements react with the animal red blood cells and induce lysis, causing the solution to turn pink.

BCAP: This method was devised at the turn of the 21st century. It is based on immunocapture-agglutination of anti-Brucella antibodies. In a BCAP test, the patient’s blood sample is exposed to anti-total human immunoglobulin and antigen suspensions. If anti-Brucella agglutinins are present, agglutination occurs and if not, a pellet forms. Out of the three methods introduced here, BCAP is the most sensitive, capable of detecting brucellosis in both newly infected and relapsing individuals.

Polymerase chain reaction (PCR) is also a viable diagnostic method for brucellosis. It involves amplifying one of two genetic targets: BrucellaBCSP31 or 16S rRNA. Using genus-specific PCR makes this method more specific and sensitive than any serological test. Because of this, the PCR test is entirely reliable, unlike serological tests which often require a secondary diagnostic test to substantiate the results. However, PCR is complex, expensive, and requires more specialized equipment compared to the serological tests and thus is the least practical when considering the fact that brucellosis primarily affects developing countries.

Treatment

Antibiotics are a common way to treat humans with brucellosis. As with all antibiotics, some strains of Brucella have developed resistance against them, but the most epidemiologically relevant strains have thankfully remained susceptible to the classic antibiotic treatment. So far, an antibiotic regimen of six weeks of doxycycline supplemented by two or three weeks of streptomycin is the best option in terms of effectiveness, low relapse frequency, and mildest side effects. Doxycycline, a common antibiotic for treating a range of infections, is administered daily orally or via intramuscular injection, so access to appropriate equipment and care is of some concern in the poorer countries where brucellosis is most prevalent. A TMP-SMX (trimethoprim-sulfamethoxazole) with rifampin regimen is a cheaper but significantly less effective alternative. It tends to be a last resort treatment in countries that can afford other options, but in many third world countries it is the only economically feasible one.

The use of antibiotics in animals, especially those raised for food, is typically discouraged. This is because overuse of antibiotics to treat livestock has negative economic, epidemiological, and public health implications. Widespread use of antibiotics is expensive, selects for antibiotic-resistance in the bacteria, and could potentially pose a biological threat to humans who consume the treated livestock. Unfortunately, there is no ideal treatment for animal brucellosis. This is why it is especially important to implement adequate preventative measures (in both humans and animals) in areas where Brucella infection is common.

Prevention

As Themistocles Zammit discovered, one of the most common ways that humans contract brucellosis is by consuming contaminated dairy products. Fortunately, there is a simple solution to prevent this form of transmission: pasteurization. As previously mentioned, Brucella is extremely sensitive to heat so heating infected milk is a quick and reliable way to eliminate the bacteria from the product.

Figure 5. Modeling effects of brucellosis vaccines on three bovine populations. (A) Persistence of brucellosis across 40 years in three populations of cows with high (blue line, data obtained from a herd in Mato Grosso, Brazil), medium (red line, data obtained from a herd in Rodoni, Brazil), and low (black line, data obtained from a herd in Goias, Brazil) brucellosis prevalence. The solid and dotted lines delineate the pattern of persistence for the low-efficacy (30%) and high-efficacy (90%) vaccine, respectively. (B) Predictions for V_c, the amount of vaccine required to achieve herd immunity, at varying values of p as a function of R₀. V_c was calculated as 1 – (1/R₀). At higher p values, herd immunity is less likely to occur and thus the eradication of brucellosis becomes more and more improbable. [1]

Another way to prevent the spread of Brucella, one commonly implemented in countries where livestock are infected, is to slaughter and properly dispose of all infected animals, preventing further transmission. Of course, this practice is costly and impractical in areas of high prevalence.

The third and most widely practiced preventative method is prophylactic vaccination. One of the earliest forms of vaccination against brucellosis manipulated live, differentially virulent strains of B. abortus and B. melitensis. Female cattle and goats were subcutaneously vaccinated with one of the strains and artificially inseminated between two and four months after vaccination. Success was determined based on prevention of udder infection and abortion. The success rate was about 86% for the least virulent strain, and nearly 100% for the intermediate and most virulent strains. Studies have shown that the most effective means of preventing transmission and decreasing the bacteria’s abundance is by performing consistent vaccinations and quickly quarantining all infected animals. When these two preventative methods are used in conjunction with each other, the result is described as the herd immunity theory. The theory proposes that increasing the overall tolerance of the existing herd also increases the resistance of subsequent, unvaccinated generations. Unfortunately, improper administration of vaccines and other preventative methods can have detrimental effects on a host population.

Figure 6. Predictions for the development of vaccine-resistant Brucella. (A) The blue line represents the normal strain, the red line represents the resistant strain. The solid lines refer to the prevalence, the dotted lines refer to the basic reproductive ratio. (B) Vaccines with lower than 75% efficacy pose a risk for the evolution of vaccine-resistant strains. [1]

In 2014, researchers conducted a study modeling the effects of low and high-efficacy brucellosis vaccines on Brucella transmission (Figure 5). Previous studies have shown that low-efficacy vaccines are an inadequate means of eradicating certain diseases compared to higher-efficacy vaccines, and the study aimed to apply this hypothesis to brucellosis. The researchers obtained data from three cow herds with high, medium, and low prevalences of brucellosis and used mathematical models to project four decades of brucellosis persistence using a low-efficacy vaccine (30% protection rate) and a high-efficacy vaccine (90% protection rate). The models related Brucella’s basic reproductive ratio (R₀, defined as the average number of secondary infections that arise from a single infected animal, assuming a wholly susceptible population) to the fraction of unsuccessful vaccinations in the herd (p). R₀ values greater than 1 reflect efficient transmission of the disease and R₀ values less than 1 typically result in the eventual eradication of the disease. The researchers determined that in order to achieve the aforementioned herd immunity, the proportion of individuals that must be vaccinated can be calculated using the following equation: (R₀ – 1)/[R₀*(1 – p)]. Based on this, they suggested that if p is too large, herd immunity cannot be achieved and the population continues to be susceptible to brucellosis. The results of the study suggest that the administration of weak, short-term vaccines induces what they referred to as a “false sense of security” in host populations. Low efficacy vaccines are not only rather useless for preventing the transmission of the disease, but they can have deleterious long-term effects by facilitating the evolution of new subspecies of virulent Brucella, selecting for stronger pathogenicity and better transmissibility (Figure 6). Furthermore, people are less likely to take appropriate preventative measures if they are told the animals have been vaccinated, making them more vulnerable to infection. Especially in developing countries where brucellosis is most prevalent, it is more difficult to educate the general public about this false sense of security, which has resulted in several violent outbreaks of brucellosis in animals and humans in recent years. Not only that, the use of certain strains of live Brucella species in vaccines for food animals has resulted in the transmission of brucellosis to humans who consumed the vaccinated animals’ products. Research is still ongoing with regards to developing a harmless, live Brucella vaccine. The combined implementation of these three preventative measures has successfully eradicated brucellosis from practically all livestock herds and human populations in many countries, but it is still prevalent and problematic in developing countries where equipment, money, and care are less accessible.

Current Conundrums

Though brucellosis has been around even longer than modern humans have, there are still many unanswered questions and unresolved problems surrounding the genus Brucella, especially with respect to the pathogenic species. Current research is primarily directed towards developing more effective, accessible, and cheaper treatments and prevention methods. Of course, in order to achieve these goals, researchers must start at the root of understanding Brucella as a pathogen. This in itself has proven to be quite an ordeal for a couple of reasons. First, within the monophyletic genus Brucella, the different species have very different host preferences and levels of pathogenicity. Second, the pathogenic Brucella species have presented themselves as genetically anomalous pathogens. The gene sequences of pathogenic Brucella species are void of the “classic” virulence markers found in most pathogens. These include genes that code for factors such as exoenzymes, motility structures (e.g. fimbriae and flagella), toxins, lysogenic phages, and resistance forms. The details of exactly why Brucella has evolved in such a way are yet to be determined, and this discovery has led researchers to reevaluate the way they define pathogens. Indeed, the development of new treatments and prevention methods may be out of reach until this mystery is resolved.

References

Authored for BIOL 238 Microbiology, taught by Joan Slonczewski, 2017, Kenyon College.